Mostrando 4 resultados de: 4
Filtros aplicados
Publisher
Annals of the Rheumatic Diseases(2)
Clinical Reviews in Allergy and Immunology(1)
Clinical Rheumatology(1)
Área temáticas
Farmacología y terapéutica(2)
Medicina y salud(2)
Problemas sociales y servicios a grupos(2)
Área de conocimiento
Enfermedad cardiovascular(1)
Inmunología(1)
Medicina interna(1)
Salud Pública(1)
Salud pública(1)
Origen
scopus(4)
Clinical pbkp_redictors of remission and low disease activity in Latin American early rheumatoid arthritis: data from the GLADAR cohort
ArticleAbstract: Objectives: To identify baseline pbkp_redictors of remission and low disease activity (LDA) in earlyPalabras claves:Early RA outcomes, Early RA remission, Early RA response pbkp_redictors, Latin America early RAAutores:Achurra-Castillo A.F., Alarcón G.S., Andrade-Ortega L., Appenzeller S., Ballesteros F., Barile-Fabris L.A., Bianchi W.A., Caballero-Uribe C.V., Cardiel M.H., Castelar-Pinheiro G.d.R., Claudio M. Galarza-Maldonado, Da Silveira I.G., de Freitas Zerbini C.A., Esquivel-Valerio J.A., Esteva-Spinetti M.H., Gamboa-Cárdenas R.V., García de la Torre I., Guibert-Toledano M., Loreto M., Monge P., Montufar R.A., Palezuelos F.I., Pisoni C.N., Pons-Estel B.A., Radominski S.C., Rios C., Rojas-Villarraga A., Sacnun M.P., Saurit V., Soriano E.R., Teijeiro R., Ugarte-Gil M.F., Vazquez-Mellado J.Fuentes:scopusEmergency arising from patients' fear of taking antimalarials during these COVID-19 times: are antimalarials as unsafe for cardiovascular health as recent reports suggest?
OtherAbstract:Palabras claves:arthritis, rheumatoid, cardiovascular diseases, Hydroxychloroquine, outcome assessment, health careAutores:Aza A., Cabrera M., Diana Carolina Buitrago-García, Rivero W., Rojas-Villarraga A., Santos-Moreno P., Villarreal L.Fuentes:scopusExperience of telemedicine use in a big cohort of patients with rheumatoid arthritis during COVID-19 pandemic
OtherAbstract:Palabras claves:Arthritis, epidemiology, health services research, rheumatoidAutores:Aza A., Castiblanco-Montañez R.A., Chavez-Chavez J., Diana Carolina Buitrago-García, Hernández-Zambrano S.M., Rivera-Triana D.P., Rojas-Villarraga A., Santos-Moreno P., Villarreal L.Fuentes:scopusShould rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases?
ArticleAbstract: The present study aimed to assess the tolerance and efficacy of rituximab (RTX), a chimeric IgG1 monPalabras claves:CD20, Pharmacogenomics, Rheumatoid Arthritis, rituximab, Sjögren's syndrome, systemic lupus erythematosusAutores:Anaya J.M., Claudio Galarza, Mantilla R.D., Pineda-Tamayo R., Rojas-Villarraga A., Rueda J.C., Tobón G.J., Valencia D., Zurita L.Fuentes:scopus